Brian Tomkowicz is the Sr. Director of Vector Engineering and Manufacturability at The Center for Breakthrough Medicines, leading internal vector engineering efforts for LV, AAV, and Ad, as well as manufacturability assessment / platform development to support commercial manufacturing. Brian previously worked for close to a decade at Janssen Pharmaceuticals where he established Janssen’s internal gene therapy program and viral production capabilities (LV and AAV). He was a member of Janssen’s acquisition team that led to the purchase of 4 clinical-stage (Ph1/Ph2) ocular disease gene therapy programs. Brian completed two academic post-docs at the University of Pennsylvania focused on viral-induced chemokine and integrin receptor signaling. From there he took a position at a biotech start-up, Morphotek, where he rose to the level of Group Leader leading several early-stage clinical development programs for cancer antibody therapeutics. Brian has dozens of peer-reviewed publications along with multiple issued patents pertaining to novel inventions in antibody and gene therapy areas. He has a BS in Microbiology from The Pennsylvania State University and a PhD in Molecular Virology from Thomas Jefferson University.
Sr. Director of Vector Engineering and Manufacturability